ArticleNPJ breast cancer2022

Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6.

Andrew W Chung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.